» Articles » PMID: 20306726

[Hypoxia in Cancer Malignity. Review]

Overview
Journal Invest Clin
Specialty General Medicine
Date 2010 Mar 24
PMID 20306726
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia is a common characteristic of solid tumors. It contributes to local and systemic tumor progression, as well as the lack of response to radio and chemotherapy, therefore increasing the probability of tumor recurrence. The HIF-1 transcription factor is the main regulator of tumor adaptation to hypoxia stress, stimulating the expression of many genes that allow cells to survive under these conditions. Products dependent on HIF-1 factor are involved in processes of tumor progression, such as proliferation, glucose metabolism, ph-acidosis, angiogenesis and metastasis. It has become increasingly necessary to gain knowledge on the HIF-1 mechanisms of action, since it is possible to find inhibitors that could be used therapeutically against cancer. In this review, a summary is given on the role that the HIF-1 factor plays in hypoxia, as well as its implications on angiogenesis and metastasis.

Citing Articles

Deep-Red and Near-Infrared Compact Cyanine Dyes for Sensitive NAD(P)H Sensing in Live Cells and Kidney Disease Tissues.

Norouzi M, Amoli A, Zhang Y, Zhang Y, Beatty A, Jarvi A ACS Appl Bio Mater. 2024; 7(12):8552-8564.

PMID: 39589839 PMC: 11792095. DOI: 10.1021/acsabm.4c01345.


Sensitive monitoring of NAD(P)H levels within cancer cells using mitochondria-targeted near-infrared cyanine dyes with optimized electron-withdrawing acceptors.

Arachchige D, Dwivedi S, Waters M, Jaeger S, Peters J, Tucker D J Mater Chem B. 2023; 12(2):448-465.

PMID: 38063074 PMC: 10918806. DOI: 10.1039/d3tb02124f.


Systemic Delivery of Magnetogene Nanoparticle Vector for Gene Expression in Hypoxic Tumors.

Terrazas-Armendariz L, Alvizo-Baez C, Luna-Cruz I, Hernandez-Gonzalez B, Uscanga-Palomeque A, Ruiz-Robles M Pharmaceutics. 2023; 15(9).

PMID: 37765201 PMC: 10536535. DOI: 10.3390/pharmaceutics15092232.


Blood Flow Restriction in Oncological Patients: Advantages and Safety Considerations.

Vinolo-Gil M, Garcia-Campanario I, Estebanez-Perez M, Pastora-Bernal J, Rodriguez-Huguet M, Martin-Vega F Healthcare (Basel). 2023; 11(14).

PMID: 37510502 PMC: 10379018. DOI: 10.3390/healthcare11142062.


miR-210 promotes human osteosarcoma cell migration and invasion by targeting FGFRL1.

Liu X, Zhang C, Wang C, Sun J, Wang D, Zhao Y Oncol Lett. 2018; 16(2):2229-2236.

PMID: 30008923 PMC: 6036426. DOI: 10.3892/ol.2018.8939.